Behind The Landmark Weeks Case
BIRMINGHAM, Ala., Jan. 28, 2013 /PRNewswire/ -- In a landmark decision, the Alabama Supreme Court ruled on January 11, 2013, that a patient who alleges injury from a generic prescription drug can sue makers of the brandname drug for failing to warn about the product's risks. The ruling, which issued in favor of Plaintiff Danny Weeks, comes after courts across the country have rejected a similar theory of liability. In his victory, Weeks was represented by attorneys of Heninger Garrison Davis, LLC, who argued the case before the state high court.
"We now have broad daylight for our claims against the brand-makers of Reglan," commented Lew Garrison, the HGD senior partner in charge of the case. "It is a great win for Danny and vindicates our decision to sue the brand defendants." The suit is pending in federal court in Montgomery, Alabama, and has been stayed pending the Alabama Supreme Court's decision on the question whether a plaintiff allegedly harmed by a generic medicine can sue the brandmaker of the drug. The federal court certified the question to the high court.
Danny Weeks alleges that he developed tardive dyskinesia, a movement disorder, from a generic version of the acid reflux drug Reglan, and that the brand-name manufacturers of the medicine (Wyeth LLC, Pfizer Inc., and Schwarz Pharma, Inc.) failed to adequately warn about its risks. Those brand defendants asked the federal court to certify the question.
In siding with Weeks, the Supreme Court reasoned that "an omission or defect in the labeling for the brand name drug would necessarily be repeated in the generic labeling, foreseeably causing harm to a patient who ingested the generic product." The court distinguished Weeks' claims and argument from several prior decisions in favor of brand-makers sued by patients who ingest only the generic versions of a drug. Chris Hood, another of Weeks' attorneys at HGD, called the decision "compelling and well reasoned.""The Alabama Supreme Court is the first and only supreme court of any state to adopt the theory of liability we advocate," Hood said. "It correctly identified and applied basic tort principles overlooked by numerous lower courts which rejected similar theories," he added. "The win is tremendously satisfying, particularly because it makes clear that Danny has recourse for his injuries."
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV